Experimental Drug Ramucirumab Improves Chemotherapy Impact on Lung Cancer Patients

June 1, 2014 12:44 AM

15 0

Experimental Drug Ramucirumab Improves Chemotherapy Impact on Lung Cancer Patients

An experimental drug, ramucirumab, has been found to extend the life of patients with advanced lung cancer. The drug has been found to increase the survival by more than a month in patients who relapsed after chemotherapy treatment.

In a clinical trial, the impact of Eli Lilly and Co.'s drug Cyramza was tested on 1,200 patients. In April 2014, FDA approved Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progr...

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...